Marcelo Negrao
@mvnegrao
Followers
367
Following
314
Statuses
100
Thoracic Medical Oncologist @MDAndersonNews #endcancer #lungcancer - tweets are my own
Houston, TX
Joined May 2019
Our manuscript is out @CCR_AACR - great team work to improve #lcsm pt outcomes @MDAndersonNews @KRASKickers @LungCancerRx @VJOncology @DavidHongMD @skopetz Impact of co-mutations and transcriptional signatures in NSCLC patients treated with adagrasib
2
9
42
RT @jitcancer: New #JITC article: Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable no…
0
5
0
RT @DrJNaidoo: 🔥Ph III KN867 trial of SBRT+concurrent/adjuvant pembrolizumab stopped early due to higher AEs in IO arm, &lack of EFS&OS ben…
0
13
0
0
3
0
RT @DAVAOnc: Starting Now: Monotherapy Data with Agents Targeting KRAS G12C Mutations Moderated By: Dr. John Heymach @MDAndersonNews
#DAVA…
0
1
0
RT @KE_Gallaway: There is no shortage of novel KRAS G12C inhibitors! @mvnegrao highlights the unmet need of patients who do not respond to…
0
2
0
RT @DAVAOnc: Starting Now: RAS Inhibitor Combinations Moderated by: Dr. John Heymach @MDAndersonNews
#DAVAHawaiiLung
0
1
0
0
3
0
RT @DAVAOnc: Starting Now: Novel Bispecifics, ADCs, and Radiation Sensitizers in Head and Neck Cancer Moderated by: @HosseinBorghaei
#DAVA…
0
4
0
RT @oncodaily: In-depth review of BRAF mutant NSCLC by Dr. @mvnegrao at Texas Lung 24 Conference - @chulkimMD
@ClinicalLung @MDAndersonNew…
0
3
0
RT @LeXiuning: In beautiful Austin for Texas Lung Conference #TexasLung24 @TLCconference with colleagues from all around the nation and fro…
0
4
0
Powerful and heartfelt kickoff to the #TexasLung24 @TLCconference - looking forward to an incredible event
0
2
8
Excited to present our work on genomic determinants of response to KRAS G12C inhibitors - looking forward to an exciting session tomorrow #AACR24 #LCSM #KRAS @MDAndersonNews @KRASKickers
MD Anderson research presentations at #AACR24 include clinical trial results for novel combination therapies, insights on treatment resistance, tumor microbiomes and HPV screening. Learn more: @mvnegrao @yejingge @GolnazMorad @JenWargoMD @GlitzaMDPhD @tcellsrus @JianHu_Neural @AACR #EndCancer
0
2
23
RT @StephenVLiu: FDA approves FLAURA 2: first line osimertinib plus chemotherapy for advanced #EGFR NSCLC. Adding chemotherapy improved PFS…
0
41
0
Important work further demonstrating the intra-cranial efficacy of KRAS G12Ci in NSCLC @JCOPO_ASCO Ezra Bernstein @JSabari @Jia_Luo Kaiwen Wang Pasi Janne
0
1
8
RT @LaurenByersMD: Congratulations to our Thoracic/HN Medical Oncology teams for a great research retreat. Excited for all of the great sci…
0
4
0
Really proud to see a Phase 3 trial fully conducted in Brazil with a vaccine developed in the Instituto Butantã - congratulations to all those involved in the trial and thank you to all those that participated in the trial!
Dengue outbreaks can affect 390 million persons yearly. In a trial involving 16,235 persons in Brazil, the live, attenuated, tetravalent Butantan vaccine was efficacious in all age groups at 2 years. Read the full trial results:
0
1
18